Asthma
Therapeutic area
Pulmonology
Rare disease
No
- Definition
- A bronchial disease that is characterized by chronic inflammation and narrowing of the airways, which is caused by a combination of environmental and genetic factors resulting in recurring periods of wheezing (a whistling sound while breathing), chest tightness, shortness of breath, mucus production and coughing. The symptoms appear due to a variety of triggers such as allergens, irritants, respiratory infections, weather changes, exercise, stress, reflux disease, medications, foods and emotional anxiety.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Asthma
- Therapeutic area
- Pulmonology
- asthma
- chronic obstructive asthma
- chronic obstructive asthma with acute exacerbation
- chronic obstructive asthma with status asthmaticus
- exercise induced asthma
- exercise-induced asthma
- All therapeutic areas
- Pulmonology
- Severity
- Mild
- MONDO ID
- MONDO:0004979
- Parent condition
- MONDO:0001358
Related records
Broader conditions (6)
- Bronchial disorder
- Disease
- Disease by body system or component
- Human disease
- Lower respiratory tract disorder
- Respiratory system disorder
Narrower conditions (18)
- Acute asthma
- Allergic asthma
- Aspirin-induced respiratory disease
- Childhood onset asthma
- Chronic asthma
- Cough variant asthma
- Environmental induced asthma
- Exercise-induced bronchoconstriction
- Extrinsic asthma
- Intermittent asthma
- Intrinsic asthma
- Isocyanate induced asthma
- Near-fatal asthma
- Nocturnal asthma
- Occupational asthma
- Status asthmaticus
- T2-high asthma
- T2-low asthma
Trials (4,499)
- "First-in-human" Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers
- "SEVERE ASTHMA" in the COMMUNITY
- "Studio NaVA" - National Study on Quality of Life in Adolescents Affected by Allergic Rhinitis With or Without Asthma
- "Turkish Validation and Reliability Study of the Brompton Breathing Pattern Assessment Tool in Asthma Patients"
- (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)
- 12-Week Study in Adult Subjects With Asthma
- 3TR Asthma Biologics Cohort (ABC) Study
- 4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
- 4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
- 45th Multicenter Airway Research Collaboration
- 6-Minute Pegboard and Ring Test Unsupported Arm Function Exercise Test in Asthma Patients
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
- A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
- A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
- A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
- A 12-Week Study in Adult Subjects With Asthma
- A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
- A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
- A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
- A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
Approved drugs (51)
- Aclidinium bromide
- Albuterol
- Albuterol sulfate
- Aminophylline
- Beclomethasone dipropionate
- Benralizumab
- Betamethasone acetate
- Budesonide
- Ciclesonide
- Cortisone acetate
- Cromolyn sodium
- Dexamethasone
- Dexamethasone sodium phosphate
- Dupilumab
- Ephedrine hydrochloride
- Ephedrine sulfate
- Epinephrine
- Flunisolide
- Fluticasone furoate
- Fluticasone propionate
Drugs in development (295)
- Abediterol Phase 2
- Ablukast Phase 3
- Acreozast Phase 2
- Adalimumab Phase 2
- ADC3680 Phase 2
- Aderamastat Phase 1
- Adriforant Phase 1
- Alanine Phase 2
- Alendronic acid Phase 2
- Alprazolam Phase 1
- AM-211 Phase 1
- Ambrisentan Phase 2
- Amelubant Phase 2
- Amlitelimab Phase 2
- Amoxicillin Phase 2
- Anakinra Phase 1
- Anrukinzumab Phase 2
- Anti-psgl-1 antibody SELK2 Phase 2
- Antipyrine Phase 2
- Apocynin Phase 1
Other linked drugs (43)
- Acetaminophen
- Asobamast
- Bambuterol
- Beclomethasone
- Bitolterol
- CEP-1347
- Chymotrypsin
- Cinalukast
- Citalopram
- Clinprost
- Cromolyn
- Darbufelone
- Efipladib
- Enprofylline
- Ephedrine
- Etoricoxib
- Fluprednisolone
- Glycerol, iodinated
- Glycopyrronium tosylate
- Ipratropium